https://www.selleckchem.com/pr....oducts/lazertinib-yh
Correlating patient outcomes with length of stay (LoS) is an important consideration in metabolic and bariatric surgery. At present, conflicting data exists regarding patient safety for ambulatory (AM metabolic and bariatric surgery. Outcomes for AMB-metabolic and bariatric surgery patients (LoS 1 d) undergoing laparoscopic Roux-en-Y gastric bypass (RYG or sleeve gastrectomy (SG) were compared with matched patients with LoS ≥1 day (non-AM using the Metabolic and Bariatric Surgery Accreditation and Quality I